Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Lancet Oncol. 2016 Nov 4;17(12):1661–1671. doi: 10.1016/S1470-2045(16)30561-7

Table 2.

Efficacy endpoints

Erlotinib (n=38) Cabozantinib (n=38) Erlotinib plus Cabozantinib (n=35)
Progression-free survival
Deaths or disease progression 36 (95%) 34 (89%) 30 (86%)
Median progression-free survival, months (95% CI) 1.8 (1.7–2.2) 4.3 (3.6–7.4) 4.7 (2.4–7.4)
Overall survival
Deaths 30 (79%) 29 (76%) 19 (54%)
Median overall survival, months (95% CI) 5.1 (3.3–9.3) 9.2 (5.1–15.0) 13.3 (7.6-NR)
Best overall response
Complete response 0 0 0
Partial response 1 (3%) 4 (11%) 1 (3%)
Stable disease 6 (16%) 19 (50%) 16 (46%)
Progressive disease 25 (66%) 9 (24%) 8 (23%)
Not evaluable/not assessed 6 (16%) 6 (16%) 10 (29%)

Data are n (%) unless otherwise indicated. NR = not reached